The Clinical Significance and Biological Function of PCDH7 in Cervical Cancer

References

• Tsikouras P, Zervoudis S, Manav B, et al. Cervical cancer: screening, diagnosis and staging. J BUON. 2016;21(2):320–325.27273940
   PubMed Web of Science ®Google Scholar
• Vu M, Yu J, Awolude OA, Chuang L. Cervical cancer worldwide. Curr Probl Cancer. 2018;42(5):457–465. doi:10.1016/j.currproblcancer.2018.06.00330064936
   PubMed Web of Science ®Google Scholar
• Zhang S, McNamara M, Batur P. Cervical cancer screening: what’s new? Updates for the busy clinician. Am J Med. 2018;131(6):702.e701–702.e705. doi:10.1016/j.amjmed.2018.01.020
   Web of Science ®Google Scholar
• Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev. 2013;2:35. doi:10.1186/2046-4053-2-3523706117
   PubMedGoogle Scholar
• Takekuma M, Kasamatsu Y, Kado N, et al. The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I-II cervical cancer: a review. J Obstet Gynaecol Res. 2017;43(4):617–626. doi:10.1111/jog.1328228190285
   PubMed Web of Science ®Google Scholar
• Shrestha AD, Neupane D, Vedsted P, Kallestrup P. Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review. Asian Pac J Cancer Prev. 2018;19(2):319–324. doi:10.22034/APJCP.2018.19.2.31929479954
   PubMedGoogle Scholar
• Lopez MS, Baker ES, Maza M, et al. Cervical cancer prevention and treatment in Latin America. J Surg Oncol. 2017;115(5):615–618. doi:10.1002/jso.2454428168717
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Practice bulletin No. 168: cervical cancer screening and prevention. Obstet Gynecol. 2016;128(4):e111–130.27661651
   PubMed Web of Science ®Google Scholar
• Kori M, Yalcin Arga K. Potential biomarkers and therapeutic targets in cervical cancer: insights from the meta-analysis of transcriptomics data within network biomedicine perspective. PLoS One. 2018;13(7):e0200717. doi:10.1371/journal.pone.020071730020984
   PubMed Web of Science ®Google Scholar
• Kori M, Gov E, Arga KY. Novel genomic biomarker candidates for cervical cancer as identified by differential co-expression network analysis. OMICS. 2019;23(5):261–273. doi:10.1089/omi.2019.002531038390
   PubMed Web of Science ®Google Scholar
• Hirayama T, Yagi T. Regulation of clustered protocadherin genes in individual neurons. Semin Cell Dev Biol. 2017;69:122–130. doi:10.1016/j.semcdb.2017.05.02628591566
   PubMed Web of Science ®Google Scholar
• Peek SL, Mah KM, Weiner JA. Regulation of neural circuit formation by protocadherins. Cell Mol Life Sci. 2017;74(22):4133–4157.28631008
   PubMed Web of Science ®Google Scholar
• Kim SY, Yasuda S, Tanaka H, Yamagata K, Kim H. Non-clustered protocadherin. Cell Adh Migr. 2011;5(2):97–105. doi:10.4161/cam.5.2.1437421173574
   PubMed Web of Science ®Google Scholar
• Wang C, Chen A, Ruan B, et al. PCDH7 inhibits the formation of homotypic cell-in-cell structure. Front Cell Dev Biol. 2020;8:329. doi:10.3389/fcell.2020.0032932457908
   PubMed Web of Science ®Google Scholar
• Xiao H, Sun Z, Wan J, Hou S, Xiong Y. Overexpression of protocadherin 7 inhibits neuronal survival by downregulating BIRC5 in vitro. Exp Cell Res. 2018;366(1):71–80. doi:10.1016/j.yexcr.2018.03.01629548751
   PubMed Web of Science ®Google Scholar
• Huang LP, Adelson ME, Mordechai E, Trama JP. CIP2A expression is elevated in cervical cancer. Cancer Biomarkers. 2010;8(6):309–317. doi:10.3233/CBM-2011-022022072119
   PubMed Web of Science ®Google Scholar
• Wu DM, Shi J, Liu T, Deng SH, Han R, Xu Y. Integrated analysis reveals down-regulation of SPARCL1 is correlated with cervical cancer development and progression. Cancer Biomarkers. 2018;21(2):355–365. doi:10.3233/CBM-17050129103025
   PubMed Web of Science ®Google Scholar
• Cao J, Wang M, Wang T. CCAAT enhancer binding protein β has a crucial role in regulating breast cancer cell growth via activating the TGF-β-Smad3 signaling pathway. Exp Ther Med. 2017;14(2):1554–1560. doi:10.3892/etm.2017.465928810620
   PubMed Web of Science ®Google Scholar
• Liu Y, Peng K, Xie R, et al. Protocadherin γ-A7 is down-regulated in colorectal cancer and associated with the prognosis in patients with wild-type KRAS. Hum Pathol. 2019;83:14–21. doi:10.1016/j.humpath.2018.08.00730121367
   PubMed Web of Science ®Google Scholar
• Terry S, Queires L, Gil-diez-de-medina S, et al. Protocadherin-PC promotes androgen-independent prostate cancer cell growth. Prostate. 2006;66(10):1100–1113. doi:10.1002/pros.2044616637074
   PubMed Web of Science ®Google Scholar
• Zhou X, Updegraff BL, Guo Y, et al. PROTOCADHERIN 7 acts through SET and PP2A to potentiate MAPK signaling by EGFR and KRAS during lung tumorigenesis. Cancer Res. 2017;77(1):187–197. doi:10.1158/0008-5472.CAN-16-1267-T27821484
   PubMed Web of Science ®Google Scholar
• Lin YL, Wang YL, Fu XL, Li WP, Wang YH, Ma JG. Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer. Oncotarget. 2016;7(19):28384–28392. doi:10.18632/oncotarget.863527070091
   PubMedGoogle Scholar
• Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009;105(2):107–108. doi:10.1016/j.ijgo.2009.02.00919342051
   PubMed Web of Science ®Google Scholar
• Wuerthner BA, Avila-Wallace M. Cervical cancer: screening, management, and prevention. Nurse Pract. 2016;41(9):18–23. doi:10.1097/01.NPR.0000490390.43604.5f
   PubMedGoogle Scholar
• Hillemanns P, Soergel P, Hertel H, Jentschke M. Epidemiology and early detection of cervical cancer. Oncol Res Treat. 2016;39(9):501–506. doi:10.1159/00044838527614953
   PubMed Web of Science ®Google Scholar
• Jiang Z, Zhou W, Li XG, et al. [The methylation analysis of EMP3 and PCDH-gamma-A11 gene in human glioma]. Zhonghua Wai Ke Za Zhi [Chin J Surg]. 2010;48(4):300–304. Chinese.
   PubMedGoogle Scholar
• Vega-Benedetti AF, Loi E, Moi L, et al. Clustered protocadherins methylation alterations in cancer. Clin Epigenetics. 2019;11(1):100. doi:10.1186/s13148-019-0695-031288858
   PubMed Web of Science ®Google Scholar
• Chen HF, Ma RR, He JY, et al. Protocadherin 7 inhibits cell migration and invasion through E-cadherin in gastric cancer. Tumour Biol. 2017;39(4):1010428317697551. doi:10.1177/101042831769755128381163
   PubMedGoogle Scholar
• Bujko M, Kober P, Mikula M, Ligaj M, Ostrowski J, Siedlecki JA. Expression changes of cell-cell adhesion-related genes in colorectal tumors. Oncol Lett. 2015;9(6):2463–2470. doi:10.3892/ol.2015.310726137091
   PubMed Web of Science ®Google Scholar
• Shishodia G, Koul S, Koul HK. Protocadherin 7 is overexpressed in castration resistant prostate cancer and promotes aberrant MEK and AKT signaling. Prostate. 2019;79(15):1739–1751. doi:10.1002/pros.2389831449679
   PubMed Web of Science ®Google Scholar
• Han GH, Chay DB, Nam S, Cho H, Chung JY, Kim JH. Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer. BMC Cancer. 2019;19(1):1202. doi:10.1186/s12885-019-6406-631823759
   PubMed Web of Science ®Google Scholar
• Zhang B, Gui LS, Zhao XL, Zhu LL, Li QW. FOXO1 is a tumor suppressor in cervical cancer. Genet Mol Res. 2015;14(2):6605–6616. doi:10.4238/2015.June.18.326125868
   PubMed Web of Science ®Google Scholar
• Li AM, Tian AX, Zhang RX, Ge J, Sun X, Cao XC. Protocadherin-7 induces bone metastasis of breast cancer. Biochem Biophys Res Commun. 2013;436(3):486–490. doi:10.1016/j.bbrc.2013.05.13123751349
   PubMed Web of Science ®Google Scholar